New insights into autoimmune liver diseases

Autoinflammatory liver disease represents an important aspect of global hepatological practice. The three principal disease divisions recognized are autoimmune hepatitis, primary sclerosing cholangitis and primary biliary cirrhosis. Largely, but not exclusively, these diseases are considered to be autoimmune in origin. Increased recognition of outlier and overlap syndromes, changes in presentation and natural history, as well as the increased awareness of IgG4‐associated sclerosing cholangitis, all highlight the limitations of the classic terminology. New insights continue to improve the care given to patients, and have arisen from carefully conducted clinical studies, therapeutic trials, as well as genetic and laboratory investigations. The challenges remain to treat patients before liver injury becomes permanent and to prevent the development of organ failure.

[1]  A. Czaja Animal models of autoimmune hepatitis , 2010, Expert Review of Gastroenterology & Hepatology.

[2]  B. Shen,et al.  Serum proteomic-based analysis for the identification of a potential serological marker for autoimmune hepatitis. , 2008, Biochemical and biophysical research communications.

[3]  M. Haider,et al.  Prevalence of sclerosing cholangitis in adults with autoimmune hepatitis: Evaluating the role of routine magnetic resonance imaging , 2008, Hepatology.

[4]  Y. Shiratori,et al.  Human leukocyte antigen DR status and clinical features in Japanese patients with type 1 autoimmune hepatitis , 2008, Hepatology research : the official journal of the Japan Society of Hepatology.

[5]  I. Mackay,et al.  The causes of primary biliary cirrhosis: Convenient and inconvenient truths , 2007, Hepatology.

[6]  T. Karlsen,et al.  Cholangiocarcinoma in primary sclerosing cholangitis is associated with NKG2D polymorphisms , 2007, Hepatology.

[7]  R. Rippe,et al.  Pivotal role of Smad3 in a mouse model of T cell–mediated hepatitis , 2007, Hepatology.

[8]  L. Boon,et al.  Coculture of human liver macrophages and cholangiocytes leads to CD40‐dependent apoptosis and cytokine secretion , 2007, Hepatology.

[9]  B. Portmann,et al.  Impact of gender on the long-term outcome and survival of patients with autoimmune hepatitis. , 2008, Journal of hepatology.

[10]  R. Flavell,et al.  Natural killer T cells exacerbate liver injury in a transforming growth factor beta receptor II dominant-negative mouse model of primary biliary cirrhosis. , 2008, Hepatology.

[11]  R. Flavell,et al.  Natural killer T cells exacerbate liver injury in a transforming growth factor β receptor II dominant‐negative mouse model of primary biliary cirrhosis , 2007 .

[12]  M. Torbenson,et al.  The impact of ethnicity on the natural history of autoimmune hepatitis , 2007, Hepatology.

[13]  M. Kaplan,et al.  Quality of life and everyday activities in patients with primary biliary cirrhosis , 2007, Hepatology.

[14]  T. Karlsen,et al.  Genetic epidemiology of primary sclerosing cholangitis. , 2007, World journal of gastroenterology.

[15]  S. Friedman,et al.  Transplantation trends in primary biliary cirrhosis. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[16]  William M. Lee,et al.  AUTOIMMUNE, CHOLESTATIC AND BILIARY DISEASE Antimitochondrial Antibodies in Acute Liver Failure: Implications for Primary Biliary Cirrhosis , 2007 .

[17]  G. Kaplan,et al.  Population‐based analysis of practices and costs of surveillance for colonic dysplasia in patients with primary sclerosing cholangitis and colitis , 2007, Inflammatory bowel diseases.

[18]  W. Lees,et al.  Autoimmune Pancreatitis: Clinical and Radiological Features and Objective Response to Steroid Therapy in a UK Series , 2007, The American Journal of Gastroenterology.

[19]  M. Mori,et al.  Comparison of the Clinical Features of Japanese Patients with Primary Biliary Cirrhosis in 1999 and 2004: Utilization of Clinical Data When Patients Applied to Receive Public Financial Aid , 2007, Journal of epidemiology.

[20]  B. Mcgarity,et al.  Autoimmune hepatitis following infliximab therapy for ankylosing spondylitis , 2007, The Medical journal of Australia.

[21]  G. Gores,et al.  Cholangiocarcinoma: is transplantation an option? For whom? , 2007, Journal of hepatology.

[22]  A. Lohse,et al.  De novo autoimmune hepatitis after liver transplantation , 2007, Hepatology research : the official journal of the Japan Society of Hepatology.

[23]  E. Seward,et al.  The use of immunoglobulin g4 immunostaining in diagnosing pancreatic and extrapancreatic involvement in autoimmune pancreatitis. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[24]  M. Solaymani-Dodaran,et al.  Influence of ursodeoxycholic acid on the mortality and malignancy associated with primary biliary cirrhosis: A population‐based cohort study , 2007, Hepatology.

[25]  T. Manabe,et al.  Histological recurrence of autoimmune liver diseases after living‐donor liver transplantation , 2007, Hepatology research : the official journal of the Japan Society of Hepatology.

[26]  S. Kawa,et al.  Sclerosing cholangitis associated with autoimmune pancreatitis , 2007, Hepatology research : the official journal of the Japan Society of Hepatology.

[27]  M. Vergara,et al.  Incidence, prevalence and clinical course of primary biliary cirrhosis in a Spanish community , 2007, European journal of gastroenterology & hepatology.

[28]  A. Montano‐Loza,et al.  Features associated with treatment failure in type 1 autoimmune hepatitis and predictive value of the model of end‐stage liver disease , 2007, Hepatology.

[29]  J. Zieleński,et al.  Primary sclerosing cholangitis in childhood is associated with abnormalities in cystic fibrosis-mediated chloride channel function. , 2007, The Journal of pediatrics.

[30]  E. Dickson,et al.  Increased prevalence of antimitochondrial antibodies in first‐degree relatives of patients with primary biliary cirrhosis , 2007, Hepatology.

[31]  T. Kogure,et al.  Fulminant hepatic failure in a case of autoimmune hepatitis in hepatitis C during peg-interferon-alpha 2b plus ribavirin treatment. , 2007, World journal of gastroenterology.

[32]  Y. Nakanuma,et al.  Immunoglobin G4‐hepatopathy: Association of immunoglobin G4‐bearing plasma cells in liver with autoimmune pancreatitis , 2007, Hepatology.

[33]  K. Zatloukal,et al.  A new xenobiotic-induced mouse model of sclerosing cholangitis and biliary fibrosis. , 2007, The American journal of pathology.

[34]  C. Selmi,et al.  Preferential X chromosome loss but random inactivation characterize primary biliary cirrhosis , 2007, Hepatology.

[35]  M. Hussain,et al.  Cytochrome P450IID6‐specific CD8 T cell immune responses mirror disease activity in autoimmune hepatitis type 2 , 2007, Hepatology.

[36]  M. Manns,et al.  Selenocysteine, soluble liver antigen/liver‐pancreas, and autoimmune hepatitis , 2007, Hepatology.

[37]  E. Heathcote Diagnosis and management of cholestatic liver disease. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[38]  D. Samuel,et al.  Usefulness of corticosteroids for the treatment of severe and fulminant forms of autoimmune hepatitis , 2007, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[39]  R. Gish,et al.  Mycophenolate mofetil in autoimmune hepatitis patients not responsive or intolerant to standard immunosuppressive therapy. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[40]  E. Distrutti,et al.  Targeting farnesoid X receptor for liver and metabolic disorders. , 2007, Trends in molecular medicine.

[41]  D. Rost,et al.  The incidence of cholangiocarcinoma in primary sclerosing cholangitis after long-time treatment with ursodeoxycholic acid , 2007, European journal of gastroenterology & hepatology.

[42]  E. Björnsson,et al.  Immunoglobulin G4 associated cholangitis: Description of an emerging clinical entity based on review of the literature , 2007, Hepatology.

[43]  David C. Jones,et al.  Population prevalence and symptom associations of autonomic dysfunction in primary biliary cirrhosis , 2007, Hepatology.

[44]  D. Vergani,et al.  Anti‐gp210 antibody mirrors disease severity in primary biliary cirrhosis , 2007, Hepatology.

[45]  J. Talwalkar,et al.  Overlap of Autoimmune Hepatitis and Primary Biliary Cirrhosis: Long-Term Outcomes , 2007, The American Journal of Gastroenterology.

[46]  N. Sasahira,et al.  Long-term prognosis of autoimmune pancreatitis with and without corticosteroid treatment , 2007, Gut.

[47]  K. Okazaki,et al.  Treatment for autoimmune pancreatitis: consensus on the treatment for patients with autoimmune pancreatitis in Japan , 2007, Journal of Gastroenterology.

[48]  Myung-Hwan Kim,et al.  Diagnostic criteria for autoimmune chronic pancreatitis , 2007, Journal of Gastroenterology.

[49]  S. Chari Diagnosis of autoimmune pancreatitis using its five cardinal features: introducing the Mayo Clinic's HISORt criteria , 2007, Journal of Gastroenterology.

[50]  S. McCall,et al.  Bile ductules and stromal cells express hedgehog ligands and/or hedgehog target genes in primary biliary cirrhosis , 2007, Hepatology.

[51]  J. Talwalkar,et al.  Tacrolimus for the treatment of primary sclerosing cholangitis , 2007, Liver international : official journal of the International Association for the Study of the Liver.

[52]  A. Montano‐Loza,et al.  Improving the End Point of Corticosteroid Therapy in Type 1 Autoimmune Hepatitis to Reduce the Frequency of Relapse , 2007, The American Journal of Gastroenterology.

[53]  David C. Jones,et al.  Biliary epithelial‐mesenchymal transition in posttransplantation recurrence of primary biliary cirrhosis , 2007, Hepatology.

[54]  A. Czaja,et al.  Current therapy for autoimmune hepatitis , 2007, Nature Clinical Practice Gastroenterology &Hepatology.

[55]  A. Zinsmeister,et al.  Risk Factors for Colorectal Neoplasia in Inflammatory Bowel Disease: A Nested Case–Control Study From Copenhagen County, Denmark and Olmsted County, Minnesota , 2007, The American Journal of Gastroenterology.

[56]  R. Coppel,et al.  A sensitive bead assay for antimitochondrial antibodies: Chipping away at AMA‐negative primary biliary cirrhosis , 2007, Hepatology.

[57]  F. Alvarez,et al.  Pathogenesis of autoimmune hepatitis: from break of tolerance to immune-mediated hepatocyte apoptosis. , 2007, Translational research : the journal of laboratory and clinical medicine.

[58]  E. Rigopoulou,et al.  Development of antimitochondrial antibodies in patients with autoimmune hepatitis: Art of facts or an artifact? , 2007, Journal of gastroenterology and hepatology.

[59]  P. Donaldson,et al.  A functional Fas promoter polymorphism is associated with a severe phenotype in type 1 autoimmune hepatitis characterized by early development of cirrhosis. , 2007, Tissue antigens.

[60]  A. Barkun,et al.  The roles of magnetic resonance and endoscopic retrograde cholangiopancreatography (MRCP and ERCP) in the diagnosis of patients with suspected sclerosing cholangitis: a cost-effectiveness analysis. , 2007, Endoscopy.

[61]  S. Kawa,et al.  A genomewide DNA microsatellite association study of Japanese patients with autoimmune hepatitis type 1 , 2007, Hepatology.

[62]  周建英,et al.  Overlap syndrome , 2007 .

[63]  Masahiro Ito,et al.  Anti‐gp210 and anti‐centromere antibodies are different risk factors for the progression of primary biliary cirrhosis , 2007, Hepatology.

[64]  E. Björnsson,et al.  Autoimmune hepatitis among fertile women: Strategies during pregnancy and breastfeeding? , 2007, Scandinavian journal of gastroenterology.

[65]  A. Bergquist,et al.  Changes over a 20-year period in the clinical presentation of primary sclerosing cholangitis in Sweden , 2007, Scandinavian journal of gastroenterology.

[66]  T. Karlsen,et al.  Genetic Polymorphisms Associated With Inflammatory Bowel Disease Do Not Confer Risk for Primary Sclerosing Cholangitis , 2007, American Journal of Gastroenterology.

[67]  M. Manns,et al.  Characterization, Outcome, and Prognosis in 273 Patients with Primary Sclerosing Cholangitis: A Single Center Study , 2005, The American Journal of Gastroenterology.

[68]  E. Heathcote Award Lecture: Past, Present and future of hepatology , 2007 .

[69]  F. Miller,et al.  Correlation Between Findings on MRCP and Gadolinium-Enhanced MR of the Liver and a Survival Model for Primary Sclerosing Cholangitis , 2007, Digestive Diseases and Sciences.

[70]  Y. Hiasa,et al.  Clinical features of symptomatic primary biliary cirrhosis initially complicated with esophageal varices , 2007, Journal of Gastroenterology.

[71]  M. Trauner,et al.  Primary sclerosing cholangitis – The arteriosclerosis of the bile duct? , 2007, Lipids in Health and Disease.

[72]  G. Gores,et al.  Cholangiocarcinoma: modern advances in understanding a deadly old disease. , 2006, Journal of hepatology.

[73]  I. Mackay,et al.  IL‐2 receptor α−/− mice and the development of primary biliary cirrhosis , 2006 .

[74]  E. Heathcote,et al.  Sclerosing cholangitis: A focus on secondary causes , 2006, Hepatology.

[75]  F. Gordon Recurrent primary sclerosing cholangitis: Clinical diagnosis and long‐term management issues , 2006, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[76]  A. Mason An autoimmune biliary disease mouse model for primary biliary cirrhosis: Something for everyone , 2006, Hepatology.

[77]  A. Floreani,et al.  HLA class II alleles, genotypes, haplotypes, and amino acids in primary biliary cirrhosis: A large‐scale study , 2006, Hepatology.

[78]  A. Tanaka,et al.  Presence of antimitochondrial autoantibodies in patients with autoimmune hepatitis , 2006, Journal of gastroenterology and hepatology.

[79]  G. Gores,et al.  Primary sclerosing cholangitis: Summary of a workshop , 2006, Hepatology.

[80]  T. Smyrk,et al.  Elevated Serum IgG4 Concentration in Patients with Primary Sclerosing Cholangitis , 2006, The American Journal of Gastroenterology.

[81]  Y. Chrétien,et al.  Development of autoimmune hepatitis in patients with typical primary biliary cirrhosis , 2006, Hepatology.

[82]  J. Newton,et al.  Fatigue in primary biliary cirrhosis is associated with excessive daytime somnolence , 2006, Hepatology.

[83]  H. Kokuryu,et al.  Bezafibrate may attenuate biliary damage associated with chronic liver diseases accompanied by high serum biliary enzyme levels , 2006, Journal of Gastroenterology.

[84]  L. Arbour,et al.  Autoimmune liver disease and the Canadian First Nations Aboriginal Communities of British Columbia's Pacific Northwest. , 2006, World journal of gastroenterology.

[85]  A. Franchitto,et al.  Cholangiocytes and blood supply. , 2006, World journal of gastroenterology.

[86]  L. Raez,et al.  Successful treatment of autoimmune hepatitis and idiopathic thrombocytopenic purpura with the monoclonal antibody, rituximab: case report and review of literature , 2006, Liver international : official journal of the International Association for the Study of the Liver.

[87]  I. Mackay,et al.  NOD.c3c4 congenic mice develop autoimmune biliary disease that serologically and pathogenetically models human primary biliary cirrhosis , 2006, The Journal of experimental medicine.

[88]  R. Tongdee,et al.  MR and MRCP in the Evaluation of Primary Sclerosing Cholangitis: Current Applications and Imaging Findings , 2006, Journal of computer assisted tomography.

[89]  A. Bergquist,et al.  Primary sclerosing cholangitis can present with acute liver failure: Report of two cases. , 2006, Journal of hepatology.

[90]  Shinichiro Yamamoto,et al.  Long-term effect of bezafibrate on parameters of hepatic fibrosis in primary biliary cirrhosis , 2006, Journal of Gastroenterology.

[91]  K. Boberg,et al.  Diagnostic accuracy of magnetic resonance and endoscopic retrograde cholangiography in primary sclerosing cholangitis. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[92]  K. Tsuneyama,et al.  Liver‐targeted and peripheral blood alterations of regulatory T cells in primary biliary cirrhosis , 2006, Hepatology.

[93]  K. Shimizu,et al.  Long-term outcome of autoimmune pancreatitis after oral prednisolone therapy. , 2006, Internal medicine.

[94]  M. Hussain,et al.  Functional Study of CD4+CD25+ Regulatory T Cells in Health and Autoimmune Hepatitis1 , 2006, The Journal of Immunology.

[95]  N. Bhala,et al.  Four year follow up of fatigue in a geographically defined primary biliary cirrhosis patient cohort , 2005, Gut.

[96]  A. Granito,et al.  Antibodies to filamentous actin (F-actin) in type 1 autoimmune hepatitis , 2006, Journal of Clinical Pathology.

[97]  A. Czaja,et al.  Distinctive clinical phenotype and treatment outcome of type 1 autoimmune hepatitis in the elderly , 2006, Hepatology.

[98]  J. Rodés,et al.  Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid. , 2006, Gastroenterology.

[99]  K. Zatloukal,et al.  24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. , 2006, Gastroenterology.

[100]  A. Bergquist,et al.  Primary sclerosing cholangitis, inflammatory bowel disease, and colon cancer. , 2006, Seminars in liver disease.

[101]  K. Lindor,et al.  Primary sclerosing cholangitis: epidemiology, natural history, and prognosis. , 2006, Seminars in liver disease.

[102]  G. Gores,et al.  Primary Sclerosing Cholangitis and Cholangiocarcinoma , 2006, Seminars in liver disease.

[103]  I. Mackay,et al.  IL-2 receptor alpha(-/-) mice and the development of primary biliary cirrhosis. , 2006, Hepatology.

[104]  C. Burton Reflections on therapeutic trials in primary biliary cirrhosis , 2005 .

[105]  A. West,et al.  Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis , 2005, Hepatology.

[106]  K. Boberg,et al.  High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study. , 2005, Gastroenterology.

[107]  F. Alvarez,et al.  LKM1 autoantibodies in chronic hepatitis C infection: A case of molecular mimicry? , 2005, Hepatology.

[108]  T. Arenovich,et al.  Autoimmune hepatitis: Effect of symptoms and cirrhosis on natural history and outcome , 2005, Hepatology.

[109]  S. Kawa,et al.  Immunoglobulin G4-related lymphoplasmacytic sclerosing cholangitis that mimics infiltrating hilar cholangiocarcinoma: part of a spectrum of autoimmune pancreatitis? , 2005, Gastrointestinal endoscopy.

[110]  K. Lindor,et al.  Secondary Sclerosing Cholangitis: A Comparison to Primary Sclerosing Cholangitis , 2005, The American Journal of Gastroenterology.

[111]  N. Kerkar,et al.  Rapamycin Successfully Treats Post‐Transplant Autoimmune Hepatitis , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[112]  K. Lankarani Mycophenolate mofetil for the treatment of primary sclerosing cholangitis , 2005, Alimentary pharmacology & therapeutics.

[113]  M. Zeniya,et al.  A Cross-Sectional Study of Primary Biliary Cirrhosis in Japan: Utilization of Clinical Data When Patients Applied to Receive Public Financial Aid , 2005, Journal of epidemiology.

[114]  M. Färkkilä,et al.  Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: A three‐year randomized trial , 2005, Hepatology.

[115]  V. Balan,et al.  Lack of Association of Common Cystic Fibrosis Transmembrane Conductance Regulator Gene Mutations with Primary Sclerosing Cholangitis , 2005, The American Journal of Gastroenterology.

[116]  T. Joh,et al.  Clinical Differences Between Primary Sclerosing Cholangitis and Sclerosing Cholangitis With Autoimmune Pancreatitis , 2005, Pancreas.

[117]  M. Manns,et al.  Treatment challenges and investigational opportunities in autoimmune hepatitis , 2005, Hepatology.

[118]  B. Combes Reflections on therapeutic trials in primary biliary cirrhosis. , 2005, Hepatology.

[119]  U. Beuers,et al.  Overlap Syndromes , 2005, Seminars in liver disease.

[120]  A. Czaja Current concepts in autoimmune hepatitis. , 2005, Annals of hepatology.

[121]  E. Schrumpf,et al.  Liver transplantation for primary sclerosing cholangitis. , 2004, Journal of hepatology.

[122]  B. Aqel,et al.  Efficacy of Tacrolimus in the Treatment of Steroid Refractory Autoimmune Hepatitis , 2004, Journal of clinical gastroenterology.

[123]  F. Gavilán,et al.  Glutathione S‐transferase T1 mismatch constitutes a risk factor for de novo immune hepatitis after liver transplantation , 2004, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[124]  S. Verma,et al.  Factors Predicting Relapse and Poor Outcome in Type I Autoimmune Hepatitis: Role of Cirrhosis Development, Patterns of Transaminases During Remission and Plasma Cell Activity in the Liver Biopsy , 2004, American Journal of Gastroenterology.

[125]  H. Tilg,et al.  Regurgitation of bile acids from leaky bile ducts causes sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. , 2004, Gastroenterology.

[126]  F. Chiodo,et al.  Type 1 autoimmune hepatitis: patterns of clinical presentation and differential diagnosis of the 'acute' type. , 2004, QJM : monthly journal of the Association of Physicians.

[127]  David C. Jones,et al.  Patterns of autoimmunity in primary biliary cirrhosis patients and their families: a population-based cohort study. , 2004, QJM : monthly journal of the Association of Physicians.

[128]  A. Chetwynd,et al.  Asymptomatic primary biliary cirrhosis: clinical features, prognosis, and symptom progression in a large population based cohort , 2004, Gut.

[129]  F. Alvarez,et al.  A murine model of type 2 autoimmune hepatitis: Xenoimmunization with human antigens , 2004, Hepatology.

[130]  P. Donaldson Genetics of liver disease: immunogenetics and disease pathogenesis , 2004, Gut.

[131]  K. Lindor,et al.  Incidence and Risk Factors for Cholangiocarcinoma in Primary Sclerosing Cholangitis , 2004, American Journal of Gastroenterology.

[132]  C. Selmi,et al.  Frequency of monosomy X in women with primary biliary cirrhosis , 2004, The Lancet.

[133]  C. Gartung,et al.  Side effects of budesonide in liver cirrhosis due to chronic autoimmune hepatitis: influence of hepatic metabolism versus portosystemic shunts on a patient complicated with HCC. , 2003, World journal of gastroenterology.

[134]  P. Marotta,et al.  Liver transplantation for primary sclerosing cholangitis. , 2003, Transplantation proceedings.

[135]  David E. J. Jones Pathogenesis of primary biliary cirrhosis. , 2003, Journal of hepatology.

[136]  H. Nakajima,et al.  A new clinicopathological entity of IgG4-related autoimmune disease , 2003, Journal of Gastroenterology.

[137]  L. Tsui,et al.  Increased prevalence of CFTR mutations and variants and decreased chloride secretion in primary sclerosing cholangitis , 2003, Human Genetics.

[138]  H. Nakajima,et al.  Close relationship between autoimmune pancreatitis and multifocal fibrosclerosis , 2003, Gut.

[139]  A. Czaja,et al.  Histological features associated with relapse after corticosteroid withdrawal in type 1 autoimmune hepatitis , 2003, Liver international : official journal of the International Association for the Study of the Liver.

[140]  W. Kremers,et al.  Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. , 2001, Gastroenterology.

[141]  M. Manns,et al.  Autoantibodies and Autoantigens in Autoimmune Hepatitis , 2002, Seminars in liver disease.

[142]  F. Alvarez,et al.  DNA Vaccination Breaks Tolerance for a Neo-Self Antigen in Liver: A Transgenic Murine Model of Autoimmune Hepatitis1 , 2002, The Journal of Immunology.

[143]  K. Boberg,et al.  Patients with small duct primary sclerosing cholangitis have a favourable long term prognosis , 2002, Gut.

[144]  J. Reitsma,et al.  Natural history of primary sclerosing cholangitis and prognostic value of cholangiography in a Dutch population , 2002, Gut.

[145]  B. McMahon,et al.  Prevalence of autoimmune liver disease in Alaska natives , 2002, American Journal of Gastroenterology.

[146]  N. Kaplowitz,et al.  Immune-mediated drug-induced liver disease. , 2002, Clinics in liver disease.

[147]  A. Czaja Treatment strategies in autoimmune hepatitis. , 2002, Clinics in liver disease.

[148]  K. Boberg Prevalence and epidemiology of autoimmune hepatitis. , 2002, Clinics in liver disease.

[149]  Y. Ilan,et al.  Prognosis of Symptomatic Versus Asymptomatic Autoimmune Hepatitis: A Study of 68 Patients , 2002, Journal of clinical gastroenterology.

[150]  P. Heidenreich,et al.  Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. , 2002, Gastrointestinal endoscopy.

[151]  K. Lindor,et al.  Small‐duct primary sclerosing cholangitis: A long‐term follow‐up study , 2002, Hepatology.

[152]  Naoaki Hashimoto,et al.  Hepatocellular carcinoma and survival in patients with primary biliary cirrhosis , 2002, Hepatology.

[153]  A. Bergquist,et al.  Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. , 2002, Journal of hepatology.

[154]  F. Carrat,et al.  Primary biliary cirrhosis: incidence and predictive factors of cirrhosis development in ursodiol-treated patients. , 2002, Gastroenterology.

[155]  D. Adams,et al.  Homing of mucosal lymphocytes to the liver in the pathogenesis of hepatic complications of inflammatory bowel disease , 2002, The Lancet.

[156]  K. Boberg,et al.  Cholangiocarcinoma in Primary Sclerosing Cholangitis: Risk Factors and Clinical Presentation , 2002, Scandinavian journal of gastroenterology.

[157]  A. Czaja,et al.  Autoimmune hepatitis with incidental histologic features of bile duct injury , 2001, Hepatology.

[158]  F. Vleggaar,et al.  Jaundice in non-cirrhotic primary biliary cirrhosis: the premature ductopenic variant , 2001, Gut.

[159]  N. LaRusso,et al.  Bcl-2-dependent oxidation of pyruvate dehydrogenase-E2, a primary biliary cirrhosis autoantigen, during apoptosis. , 2001, The Journal of clinical investigation.

[160]  D. Vergani,et al.  Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: A 16‐year prospective study , 2001, Hepatology.

[161]  M. Heneghan,et al.  Management and outcome of pregnancy in autoimmune hepatitis , 2001, Gut.

[162]  N. LaRusso,et al.  High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis , 2000, American Journal of Gastroenterology.

[163]  P. D. James,et al.  Mycophenolate mofetil for maintenance of remission in autoimmune hepatitis in patients resistant to or intolerant of azathioprine. , 2000, Journal of hepatology.

[164]  P. Donaldson,et al.  Cytotoxic T lymphocyte antigen‐4 (CTLA‐4) gene polymorphisms and susceptibility to type 1 autoimmune hepatitis , 2000, Hepatology.

[165]  T. Therneau,et al.  A revised natural history model for primary sclerosing cholangitis. , 1997, Mayo Clinic proceedings.

[166]  M. Manns,et al.  International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. , 1999, Journal of hepatology.

[167]  G. Gerken,et al.  Characterization of the overlap syndrome of primary biliary cirrhosis (PBC) and autoimmune hepatitis: Evidence for it being a hepatitic form of PBC in genetically susceptible individuals , 1999, Hepatology.

[168]  F. Alvarez,et al.  Formiminotransferase cyclodeaminase is an organ-specific autoantigen recognized by sera of patients with autoimmune hepatitis. , 1999, Gastroenterology.

[169]  K. O'rourke,et al.  Asymptomatic primary biliary cirrhosis: a study of its natural history and prognosis , 1999, American Journal of Gastroenterology.

[170]  A. Czaja Frequency and nature of the variant syndromes of autoimmune liver disease , 1998, Hepatology.

[171]  O. Chazouilleres,et al.  Primary biliary cirrhosis–autoimmune hepatitis overlap syndrome: Clinical features and response to therapy , 1998, Hepatology.

[172]  M. Yoneda,et al.  Efficacy of ursodeoxycholic acid in Japanese patients with type 1 autoimmune hepatitis , 1998, Journal of gastroenterology and hepatology.

[173]  R. Coppel,et al.  Characterization of antimitochondrial antibodies in healthy adults , 1998, Hepatology.

[174]  A. Meloni,et al.  Two cytochromes P450 are major hepatocellular autoantigens in autoimmune polyglandular syndrome type 1. , 1998, Gastroenterology.

[175]  K. Lazaridis,et al.  Primary biliary cirrhosis , 1998, Springer Netherlands.

[176]  D. Jones,et al.  Hepatocellular carcinoma in primary biliary cirrhosis and its impact on outcomes , 1997, Hepatology.

[177]  E. Dickson,et al.  Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. , 1997, Gastroenterology.

[178]  L. Thomson,et al.  Allelic basis for HLA-encoded susceptibility to type 1 autoimmune hepatitis. , 1997, Gastroenterology.

[179]  L. Thomson,et al.  Associations between alleles of the major histocompatibility complex and type 1 autoimmune hepatitis , 1997, Hepatology.

[180]  E. Dickson,et al.  Use of a designer triple expression hybrid clone for three different lipoyl domain for the detection of antimitochondrial autoantibodies , 1996, Hepatology.

[181]  K. Boberg,et al.  Features of autoimmune hepatitis in primary sclerosing cholangitis: An evaluation of 114 primary sclerosing cholangitis patients according to a scoring system for the diagnosis of autoimmune hepatitis , 1996, Hepatology.

[182]  Å. Danielsson,et al.  Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. , 1996, Gut.

[183]  R. Williams,et al.  Azathioprine for long-term maintenance of remission in autoimmune hepatitis. , 1995, The New England journal of medicine.

[184]  M. Asztély,et al.  Prognostic value of cholangiography in primary sclerosing cholangitis. , 1995, European journal of gastroenterology & hepatology.

[185]  A. Freedman,et al.  Portosystemic encephalopathy after transjugular intrahepatic portosystemic shunt: Results of a prospective controlled study , 1994, Hepatology.

[186]  E. Dickson,et al.  Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. , 1994, Gastroenterology.

[187]  T. Saibara,et al.  DNA typing of HLA class II genes; DRB1*0803 increases the susceptibility of Japanese to primary biliary cirrhosis. , 1994, Journal of hepatology.

[188]  H. Inoko,et al.  HLA class II molecules and autoimmune hepatitis susceptibility in Japanese patients. , 1992, Gastroenterology.

[189]  P. Grambsch,et al.  Primary sclerosing cholangitis: value of cholangiography in determining the prognosis. , 1991, AJR. American journal of roentgenology.

[190]  T. Sasazuki,et al.  [DNA typing of HLA class II genes]. , 1990, Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme.

[191]  P. Grambsch,et al.  Primary sclerosing cholangitis: Natural history, prognostic factors and survival analysis , 1989, Hepatology.

[192]  R. Coppel,et al.  Primary structure of the human M2 mitochondrial autoantigen of primary biliary cirrhosis: dihydrolipoamide acetyltransferase. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[193]  B. Stricker,et al.  Hepatic injury associated with the use of nitrofurans: A clinicopathological study of 52 reported cases , 1988, Hepatology.

[194]  R. Coppel Primary structure of the human M2 mitochondrial autoantigen of PBC : dihydrolipoamide acetyltransferase , 1988 .

[195]  F. Alvarez,et al.  Chronic active hepatitis associated with antiliver/kidney microsome antibody type 1: A second type of “autoimmune” hepatitis , 1987, Hepatology.

[196]  R. Chapman,et al.  Primary sclerosing cholangitis: a review of its clinical features, cholangiography, and hepatic histology. , 1980, Gut.

[197]  R. N. Macsween,et al.  Hepatocellular carcinoma in primary biliary cirrhosis: report of four cases. , 1979, Gut.

[198]  J. Fevery,et al.  Long-term follow-up of chronic active hepatitis of moderate severity. , 1978, Gut.

[199]  W. Summerskill Chronic active liver disease reexamined: prognosis hopeful. , 1974, Gastroenterology.

[200]  S. Sherlock,et al.  The presentation and diagnosis of 100 patients with primary biliary cirrhosis. , 1973, The New England journal of medicine.

[201]  B. Thompson,et al.  Sclerosing Cholangitis , 2006 .

[202]  J. G. Walker,et al.  SEROLOGICAL TESTS IN DIAGNOSIS OF PRIMARY BILIARY CIRRHOSIS. , 1965, Lancet.

[203]  P. Evans,et al.  Biliary cirrhosis , 1939, Archives of disease in childhood.

[204]  Charles F. Silvester RAPID EFFUSION OF SERUM. , 1832 .